Benjamin Purow headshot
BP

Benjamin W. Purow

Professor
Unit: School of Medicine
Department: Department of Neurology
Office location and address
Neuro Oncology
21 Hospital Dr
Charlottesville, Virginia 22903
Education
Johns Hopkins School of Medicine, 1996, MD
Residency, Pediatrics, Children's National Medical Center
Fellowship, Neuro-oncology, National Institutes of Health; Pediatric Hematology/Oncology, National Institutes of Health
Biography

Benjamin Purow received his B.A. in chemistry and physics cum laude from Harvard University in 1991 and his M.D. from Johns Hopkins Medical School in 1996. From 1994-1995, he was a Howard Hughes Medical Institute (HHMI) medical student fellow in the laboratory of Hyam Levitsky at Johns Hopkins. Dr. Purow completed a residency in pediatrics at Children’s National Medical Center in Washington, DC, followed by fellowship training in pediatric hematology/oncology and in neuro-oncology at the NIH. 

Dr. Purow spent several years pursuing brain tumor research in the laboratory of Howard Fine at the NIH, during which he was the first to show a role for the Notch pathway in gliomas. He obtained his first independent position in 2006 as an assistant professor in neuro-oncology at the University of Virginia in Charlottesville.

Dr. Purow spends 75-80 percent of his time leading his laboratory and 20-25 percent in clinical care of patients with brain tumors. His laboratory focuses on the diacylglycerol kinases as targets in cancer, on microRNAs in glioblastoma and on novel ways to target the underlying molecular circuitry in brain tumors. The Purow laboratory is supported by grant awards from the NIH and from generous private donors.

Engineering ERK-specificity for cancer suicide gene therapy
Source: U.S. NIH Cancer Institute
September 01, 2020 – August 31, 2022
Crosslinking conjugates to localize and activate NK cells in glioblastoma
Source: U.S. NIH Institute of Neurological Disorders & Str
April 15, 2019 – March 31, 2022
Interstitial Fluid Flow Regulates Glioma Cell Invasion
Source: Virginia Polytechnic Institute and State Universit
December 15, 2017 – November 30, 2021
Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connexin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide
Source: FirstString Research Inc.
September 06, 2018 – August 31, 2020
MD-NEUR Novel DGKalpha Inhibitors and Immunotherapy for GBM and Melanoma Brain Metastasis
Source: U.S. NIH Cancer Institute
August 01, 2014 – July 31, 2020
Clinical Trial of New Drug in Dogs to Treat Brain Cancer in Humans
Source: Virginia Polytechnic Institute and State Universit
December 01, 2015 – May 31, 2018
MD-NEUR Targeting Diacylglycerol Kinases in Glioblastoma
Source: U.S. NIH Cancer Institute
May 06, 2014 – April 30, 2018
MD-NERS A Randomized Phase IIB Open Label Study of Nivolumab or Nivolumab in Combination with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma (GBM); CA209-143-0027
Source: Bristol-Myers Squibb Company
November 05, 2014 – November 05, 2017
Commonwealth Foundation for Cancer Research
Source: Commonwealth Cancer Foundation for Research
June 01, 2002 – December 31, 2015
MD-NEUR Investigation of Notch-Inhibiting microRNAs in Glioma
Source: U.S. NIH Cancer Institute
February 01, 2009 – December 31, 2014
MD-NEUR Investigation of Alpha-secretase Inhibitors as Notch Inhibitors and Anti-glioma a
Source: U.S. NIH Cancer Institute
September 01, 2008 – July 31, 2013
MD-NEUR microRNA-7 Targets Key Cancer Pathways and is a Potential Therapy fo rGlioma
Source: Howard Hughes Medical Institute
August 01, 2008 – July 31, 2013
NESC 3960: Research in Neuroscience
Credits: 3
Students in Neuroscience major are expected to participate in active research, supervised by a faculty research mentor. The course grade is based on 10 hours/week lab work toward achieving term goals that are determined individually at the beginning of the term. Students are expected to submit a Term Plan one month after the first day of classes and a Progress Report two weeks before the last day of classes.
NESC 4970: Distinguished Majors Thesis
Credits: 3
A two-semester course in which the student prepares a thesis under the supervision of a Neuroscience Graduate Program faculty member. The thesis must be based on empirical research conducted by the student. Prerequisite: Participant in Neuroscience DMP.
NESC 4980: Distinguished Majors Thesis
Credits: 3
A two-semester course in which the student prepares a thesis under the supervision of a Neuroscience Graduate Program faculty member. The thesis must be based on empirical research conducted by the student. Prerequisite: Participant in Neuroscience DMP.
MICR 8042: Advanced Topics in Cancer
Credits: 2
This course will cover contemporary topics relevant to the detection and treatment of solid tumors and hematopoietic cancers. These include, but are not limited to, clinical trials, metabolism and cancer, cancer stem cells, cancer biomarkers, systems and networks in cancer. Students will attend organ-based tumor boards, which expose the students to the team-based approach for individualizing treatments that is practiced in the UVA Cancer Center. Prerequisite: MICR 8040 and MICR 8044.
PATH 9995: Topical Research
Credits: 1–12
Original research on approved problems.
NESC 9998: Non-Topical Research, Preparation for Doctoral Research
Credits: 1–12
For doctoral research, taken before a dissertation director has been selected.
PATH 9999: Non-Topical Research
Credits: 1–12
Dissertation research credit for students who have completed their advancement to candidacy.
NESC 9999: Non-Topical Research
Credits: 1–12
For doctoral research, under the supervision of a dissertation director.
  • 2011-2018 Best Doctors in America® List